Incyte (INCY) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Incyte Corporation (INCY) insider buying and selling: no purchases, 40 sales
131 Form 4 Table I transactions filed with the SEC by Incyte Corporation insiders between 2025-08-27 and 2026-10-19 (15-month history): 0 open-market purchases and 40 sales, plus 91 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $19.8M by Hoppenot Herve on 2025-11-10.
Incyte insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Incyte insiders filed 35 sales worth $58.3M on the open market, and no purchases.
The biggest seller was Hoppenot Herve (Director): $19.8M in 1 sale, out of 10 different sellers.
The largest trade of the period was a sale of $19.8M on Nov 10, 2025, by Hoppenot Herve (Director), under a 10b5-1 plan. Form 4 on sec.gov (0001596492-25-000008).
All 35 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 9 sales, against 6 in the three before. The latest sale from Oct 15, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Incyte has more sales than 54 of the other 58, ranks 15 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with INCY's sales, largest first. The full history is in the tool above, already searched.
See all 131 INCY trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-10 | 2025-11-12 | Hoppenot Herve | Director | $19.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 73,486 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. | SEC |
| 2025-12-16 | 2025-12-18 | Morrissey Michael James | EVP, Head of Tech. Operations | $5.3M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-07-31 | 2026-08-04 | Mayes Patrick A | EVP & Chief Scientific Officer | $5.0M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-07-15 | 2026-07-16 | Stein Steven H | CMO & Head of Late-Stage Dev. | $3.2M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-09-15 | 2026-09-17 | Cagnoni Pablo J | President, Global Head of R&D | $2.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2025-12-02 | 2025-12-03 | Stein Steven H | EVP & Chief Medical Officer | $2.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 This includes an aggregate of 63,129 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. | SEC |
| 2026-07-31 | 2026-08-04 | Cagnoni Pablo J | President, Global Head of R&D | $1.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-02-19 | 2026-02-23 | Cagnoni Pablo J | President, R&D | $1.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-04-17 | 2026-04-21 | Cagnoni Pablo J | President, Global Head of R&D | $1.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 257,553 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-03-17 | 2026-03-19 | Cagnoni Pablo J | President, R&D | $1.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-01-05 | 2026-01-07 | Stein Steven H | EVP & Chief Medical Officer | $1.6M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 34,203 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. | SEC |
| 2026-05-19 | 2026-05-21 | Clancy Paul J | Director | $1.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. | SEC |
| 2026-08-19 | 2026-08-20 | Cagnoni Pablo J | President, Global Head of R&D | $1.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-08-05 | 2026-08-07 | Cagnoni Pablo J | President, Global Head of R&D | $1.3M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-08-12 | 2026-08-14 | Cagnoni Pablo J | President, Global Head of R&D | $1.3M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
| 2026-01-07 | 2026-01-08 | Issa Mohamed Khairie | EVP, Head of US Oncology | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 This includes an aggregate of 66,132 shares of common stock issuable pursuant to previously reported RSUs that have not vested. | SEC |
| 2026-08-03 | 2026-08-04 | Mayes Patrick A | EVP & Chief Scientific Officer | $729k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. | SEC |
| 2025-11-05 | 2025-11-07 | Stein Steven H | EVP & Chief Medical Officer | $535k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. | SEC |
| 2025-12-10 | 2025-12-12 | Mayes Patrick A | EVP & Chief Scientific Officer | $531k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-17 | 2025-12-18 | Morrissey Michael James | EVP, Head of Tech. Operations | $420k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 Includes an aggregate of 27,507 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 27, 2025 and Oct 19, 2026 there is not one open-market purchase of Incyte Corporation: 40 sales worth $58.7M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Incyte Corporation's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 40 | $58.7M |
| A | Grant or award | 39 | $254k |
| F | Tax withholding (shares surrendered for taxes) | 31 | $15.7M |
| M | Option exercise | 21 | $15.4M |
| Total | Everything filed in the period | 131 | $90.1M |
30 of the 131 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 22 distinct people or entities have filed Incyte Corporation transactions: none bought on the open market and 10 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 10 who sold on the open market (40 sales in all), the three biggest sellers account for $42.0M of the $58.7M: 72% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Hoppenot Herve | Director | 2 | — | $19.8M (1) | 2025-12-10 |
| Cagnoni Pablo J | President, Global Head of R&D | 19 | — | $14.4M (9) | 2026-10-19 |
| Stein Steven H | CMO & Head of Late-Stage Dev. | 14 | — | $7.9M (6) | 2026-07-20 |
| Mayes Patrick A | EVP & Chief Scientific Officer | 13 | — | $6.6M (5) | 2026-08-07 |
| Morrissey Michael James | EVP, Head of Tech. Operations | 7 | — | $5.7M (2) | 2026-02-04 |
| Clancy Paul J | Director | 8 | — | $1.4M (1) | 2026-10-02 |
| Issa Mohamed Khairie | EVP, Head of U.S. Commercial | 5 | — | $1.3M (2) | 2026-07-20 |
| Tray Thomas | Principal Accounting Officer | 12 | — | $879k (6) | 2026-07-20 |
Shown here are the 8 who moved the most money, out of 22. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Dec 2025: 0 purchases and 8 sales, worth $8.9M. 1 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 2 | $74k |
| Oct 2025 | 0 | $0 | 3 | $376k |
| Nov 2025 | 0 | $0 | 7 | $20.8M |
| Dec 2025 | 0 | $0 | 8 | $8.9M |
| Jan 2026 | 0 | $0 | 2 | $2.8M |
| Feb 2026 | 0 | $0 | 1 | $1.9M |
| Mar 2026 | 0 | $0 | 1 | $1.8M |
| Apr 2026 | 0 | $0 | 1 | $1.8M |
| May 2026 | 0 | $0 | 2 | $1.6M |
| Jun 2026 | 0 | $0 | 1 | $264k |
| Jul 2026 | 0 | $0 | 5 | $10.4M |
| Aug 2026 | 0 | $0 | 5 | $5.0M |
| Sep 2026 | 0 | $0 | 1 | $2.8M |
| Oct 2026 | 0 | $0 | 1 | $298k |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Incyte Corporation (INCY) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
20 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Incyte has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 19, 2026, and a Form 4 arrives up to two business days after the trade.
16 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.